Do you want to read an article? Please log in or register.
PET/CT in the Staging and Treatment Response Assessment of Patients With Extranodal Marginal Zone Lymphoma
Lymphoma
Related content
Lymphoma
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
Blood
Claudel A, Cottereau AS, Bachy E, Itti E, Feugier P, Rossi C, Lemonnier F, Camus V, Daguindau N, Cartron G, Nicolas Virelizier E, Mbouma DL, Cardoso C, Bommier C, Tessoulin B, Fruchart C, Gilbert A, Durot E, Fleck E, Pica GM, Zerazhi H, Guidez S, Cheminant M, Sarkozy C, Xerri L, Vercellino L, Trabelsi N, Gomes L, Portugues C, Viailly PJ, Delfau-Larue MH, Morschhauser F
doi: 10.1182/blood.2024027727
Lymphoma
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network)
Leuk Lymphoma
Cencini E, Palazzo M, Dardanis D, Lucco Navei G, Mannelli L, Zoi V, Mecacci B, Sordi B, Cervetti G, Rosati S, Nassi L, Bocchia M, Fabbri A
doi: 10.1080/10428194.2025.2456094
Lung, Respiratory and Thoracic Cancer
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
J Thorac Oncol
Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT
doi: 10.1016/j.jtho.2024.09.1443
Lung, Respiratory and Thoracic Cancer
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Lung Cancer
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K
doi: 10.1016/j.lungcan.2025.108104
Lymphoma
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma
Blood Cancer J
Luna A, Devlin SM, Rejeski K, Flynn JR, Corona M, Luttwak E, Rivas-Delgado A, Landego I, Cassanello G, Gomez-Llobell M, Raj SS, Dahi PB, Lin RJ, Parascondola A, Palomba ML, Shah GL, Scordo M, Alarcon Tomas A, Leithner D, Bedmutha A, Schöder H, Imber BS, Salles G, Park JH, Perales MA, Shouval R
doi: 10.1038/s41408-025-01273-1
Further Publications
Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients
Eur Radiol
Nelles C, Gräf M, Bernard P, Persigehl T, Große Hokamp N, Zopfs D, Maintz D, Kreuzberg N, Wolf J, Bröckelmann PJ, Lennartz S
doi: 10.1007/s00330-024-11060-4
Central Nervous System Tumors
Automated longitudinal treatment response assessment of brain tumors: a systematic review
Neuro Oncol
Shi T, Kujawa A, Linares C, Vercauteren T, Booth TC
doi: 10.1093/neuonc/noaf037
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [(18)F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Oncol
Vera P, Thureau S, Le Tinier F, Chaumet-Riffaud P, Hapdey S, Kolesnikov-Gauthier H, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boissellier P, Guillemard S, Salem N, Brenot-Rossi I, Le Péchoux C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Moisson P, Larrouy A, Modzelewski R, Gouel P, Ghazzar N, Langlais A, Amour E, Zalcman G, Giraud P
doi: 10.1016/S1470-2045(24)00320-6
Genitourinary Cancer
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis
Eur Urol
Mazzone E, Thomson A, Chen DC, Cannoletta D, Quarta L, Pellegrino A, Gandaglia G, Moon D, Eapen R, Lawrentschuk N, Montorsi F, Siva S, Hofman MS, Chiti A, Briganti A, Perera ML, Murphy DG
doi: 10.1016/j.eururo.2025.05.006